Al­ways chas­ing the newest sci­ence, Schond Green­way joins MindMed; Mi­rati fills key va­can­cy with ex-Are­na fi­nance chief

Schond Green­way

From cell ther­a­py to pre­ci­sion med­i­cine, Schond Green­way has hopped from one bur­geon­ing re­search area to the next through­out his ca­reer. Now he’s head­ing off to an­oth­er: psy­che­del­ic ther­a­py.

MindMed tapped Green­way as CFO on Mon­day, as CEO Robert Bar­row guides the com­pa­ny through what he called “an ex­cit­ing point in our growth.” The New York-based psy­che­delics com­pa­ny was the sec­ond to ever go pub­lic on an Amer­i­can ex­change, be­hind Com­pass Path­ways. And this year, Bar­row’s lin­ing up “nu­mer­ous near-term mile­stones ahead across our pipeline.”

“My fo­cus has al­ways been, across all the dif­fer­ent com­pa­nies that I’ve ac­tu­al­ly tried to be a part of, it’s re­al­ly fo­cus­ing on those com­pa­nies that are look­ing to have a new par­a­digm to treat­ing their par­tic­u­lar sub­sec­tor,” Green­way said.

So when a re­cruiter ap­proached him about the open­ing at MindMed, he was in­trigued. MindMed is one of sev­er­al com­pa­nies de­vel­op­ing mod­i­fied psy­che­delics in search of new and bet­ter ther­a­pies for men­tal health. One of their pro­grams, Pro­ject Lucy, in­volves a hal­lu­cino­genic dos­ing of LSD to treat anx­i­ety, ad­min­is­tered by a ther­a­pist.

Green­way didn’t start out in the phar­ma in­dus­try. He re­ceived an MBA from the Uni­ver­si­ty of Vir­ginia’s Dar­d­en Grad­u­ate School of Busi­ness in 1998, and was an in­vest­ment banker at Mor­gan Stan­ley when he helped lead an IPO for an in­ter­est­ing biotech out of the San Fran­cis­co Bay Area.

“One thing led to an­oth­er, and I end­ed up leav­ing the world of in­vest­ment bank­ing and jump­ing over to the client side,” he said.

That com­pa­ny was Durect Cor­po­ra­tion, a spin­out from the John­son & John­son sub­sidiary Alza Cor­po­ra­tion. And he hasn’t turned back.

Green­way’s ré­sumé boasts a long list of biotech and health­care-fo­cused roles, in­clud­ing at Bar­clays Cap­i­tal, Mesoblast and Halozyme. Most re­cent­ly, he was CFO at Ava­lo Ther­a­peu­tics, a small-cap biotech com­pa­ny fo­cused on pre­ci­sion ther­a­pies in im­munol­o­gy, im­muno-on­col­o­gy and rare ge­net­ic dis­ease. He stepped down in Feb­ru­ary, just weeks be­fore the com­pa­ny con­duct­ed lay­offs and shrank the pipeline.

When asked about the cur­rent bear mar­ket, he said, “This may be one of the more chal­leng­ing biotech mar­kets in re­cent mem­o­ry … But all that said, it’s al­ways im­por­tant to re­main ac­tive on the out­reach front, which is what we will con­tin­ue to do, whether it’s in per­son or vir­tu­al­ly, or at an in­vestor meet­ing or at a med­ical sci­ence meet­ing.”

With mul­ti­ple mile­stones ahead, Green­way said he hopes to avoid a “bunker” men­tal­i­ty.

“Some com­pa­nies will kind of get more in­su­lar,” he said. “I think it’s al­ways much more im­por­tant to con­tin­ue to be out ahead, be out in front, en­sure that the Street un­der­stands what our val­ue propo­si­tion is and con­tin­ue to ex­e­cute.” — Nicole De­Feud­is

Lau­rie Stelz­er

→ As the David Meek era be­gan at Mi­rati, two key mem­bers of the se­nior lead­er­ship part­ed ways short­ly there­after. COO and prin­ci­pal fi­nan­cial of­fi­cer Daniel Fa­ga — who’s now the in­ter­im CEO of Anap­tys­Bio — and CMO Joseph Lev­eque both left the com­pa­ny on Oct. 28, and now the biotech wag­ing a KRAS bat­tle with Am­gen has wel­comed Lau­rie Stelz­er as CFO. A Shire vet who was fi­nance chief at Are­na Phar­ma­ceu­ti­cals be­fore Pfiz­er snapped it up for $6.7 bil­lion, Stelz­er was CFO at Halozyme from 2015-20. Chief ac­count­ing of­fi­cer Vick­ie Reed, who had been pinch-hit­ting as in­ter­im prin­ci­pal fi­nan­cial of­fi­cer, is slat­ed to re­tire “lat­er this year.”

And with Lon­gi­tude Cap­i­tal’s David Hirsch step­ping down from the board at Po­sei­da, Mi­rati pres­i­dent and R&D chief Charles Baum en­ters as a new mem­ber of the San Diego cell and gene ther­a­py play­er’s board. Baum, the founder and CEO of Mi­rati un­til Meek took over, is the chair­man of On­coMyx Ther­a­peu­tics.

Kanya Ra­jangam

Kanya Ra­jangam’s next des­ti­na­tion has been re­vealed af­ter her res­ig­na­tion from Nkar­ta, and she’s stay­ing in the NK cell ther­a­py are­na, join­ing Tim Lu’s End­points 11 hon­oree Sen­ti Bio as chief med­ical and de­vel­op­ment of­fi­cer in Ju­ly. Ra­jangam be­came CMO of Nkar­ta in No­vem­ber 2018 and will hand the reins to David Shook, who gets the bump from se­nior med­ical di­rec­tor to VP, clin­i­cal de­vel­op­ment. A month ago, Nkar­ta tout­ed pos­i­tive da­ta for its two lead off-the-shelf NK cell ther­a­pies, help­ing shares re­cov­er from its nadir the pre­vi­ous ses­sion.

Young Kwon

Doug Tre­co has re­signed as CEO of UK mon­o­clon­al an­ti­body biotech Alchemab “for per­son­al rea­sons,” pass­ing the ba­ton to Young Kwon, who just ar­rived as chief fi­nan­cial and op­er­at­ing of­fi­cer in No­vem­ber 2021. Kwon left Bio­gen in 2011 to be­come VP, busi­ness de­vel­op­ment at Mo­men­ta, steadi­ly climb­ing to chief fi­nan­cial and busi­ness of­fi­cer be­fore J&J forked over $6.5 bil­lion for the com­pa­ny in 2020. RA Cap­i­tal led the way on Alchemab’s $82 mil­lion Se­ries A raise last spring.

Ka­trine Bosley

→ It’s been more than three years since Ka­trine Bosley made her sur­prise ex­it as Ed­i­tas CEO, but she’s now jump­ing in­to the ven­ture cap­i­tal side of things — join­ing Lon­don-based ear­ly-stage in­vestor Ad­vent Life Sci­ences as ven­ture part­ner. Bosley made an abrupt ex­it from Ed­i­tas right as the com­pa­ny was head­ing in­to its first-in-hu­man tri­al. Since then, Bosley has been ad­vis­ing biotechs such as Gala­pa­gos and Geno­cea on their boards and as chair of Michael Gilman’s Ar­rakis.

Join­ing Bosley at Ad­vent as gen­er­al part­ners are: Do­minic Schmidt, for­mer­ly of Syn­cona (who will be based in the UK) and Satish Jin­dal, most re­cent­ly the CEO of in­vest­ment fund Bio­Mo­tiv (who will be based in Boston, like Bosley).

Juli Blanche

Pre­ci­sion Bio­Sciences un­veiled da­ta at ASH in De­cem­ber for its lead can­di­date PB­CAR0191 that all but reaf­firmed the stan­dard dura­bil­i­ty con­cerns with al­lo­gene­ic CAR-Ts that ri­vals like CRISPR Ther­a­peu­tics and Al­lo­gene had grap­pled with in the past. This week the Durham, NC biotech has poached Juli Blanche from Bris­tol My­ers Squibb, nam­ing her chief peo­ple of­fi­cer. Blanche, a tal­ent ac­qui­si­tion ex­ec at Cel­gene, stuck around af­ter the buy­out and had just been pro­mot­ed to SVP and HR busi­ness part­ner, glob­al com­mer­cial­iza­tion sev­er­al months ago at the phar­ma gi­ant.

Jes­per Høi­land

Jes­per Høi­land is re­tir­ing as glob­al chief com­mer­cial of­fi­cer of As­cendis Phar­ma “to re­turn to Den­mark with his fam­i­ly,” ac­cord­ing to a re­lease. Høi­land steered the US com­mer­cial ef­forts for As­cendis’ pe­di­atric growth hor­mone de­fi­cien­cy drug, ap­proved in Au­gust 2021 and mar­ket­ed as Skytro­fa, and we cov­ered the 30-year No­vo Nordisk vet’s ap­point­ment at Peer Re­view in May 2020 af­ter his three-year run as pres­i­dent and CEO of Ra­dius Health.

As Høi­land bids farewell, the Copen­hagen biotech has pro­mot­ed Joe Kel­ly to head of US com­mer­cial, en­docrinol­o­gy and Scott Holmes to head of glob­al com­mer­cial strat­e­gy, en­docrinol­o­gy, both brand new po­si­tions. Kel­ly be­came VP of sales at As­cendis in Sep­tem­ber 2020 and, like Høi­land, held posts at Ra­dius Health and No­vo Nordisk. Holmes, whose 12 years at Cel­gene end­ed in 2018 as head of com­mer­cial ex­cel­lence, North Amer­i­ca, had been As­cendis’ VP, com­mer­cial an­a­lyt­ics ever since.

Jeff Lei­den

Gary Glick’s new biotech Odyssey Ther­a­peu­tics, burst­ing on­to the scene with a $218 mil­lion Se­ries A back in De­cem­ber which was co-led by Or­biMed and SR One, has made Jeff Lei­den chair­man of the board. The ex-chief and cur­rent ex­ec­u­tive chair­man at Ver­tex re­cent­ly stepped down as chair­man of Tmu­ni­ty, Carl June’s CAR-T play which has es­sen­tial­ly kept mum since two pa­tient deaths rat­tled the com­pa­ny near­ly a year ago.

In an­oth­er Ver­tex con­nec­tion, Odyssey has locked in Dar­ryl Patrick as EVP of non-clin­i­cal de­vel­op­ment. Fol­low­ing his 20 years with Mer­ck Re­search Lab­o­ra­to­ries, Patrick was VP, non-clin­i­cal de­vel­op­ment and VP, ex­plorato­ry de­vel­op­ment for Ver­tex from 2004-11.

John Maraganore

→ We’re see­ing move­ment on the Maraganore Me­ter again, as John Maraganore grabs an­oth­er post-Al­ny­lam gig as strate­gic ad­vi­sor for Chro­ma Med­i­cine, the At­las-backed gene edit­ing start­up that raised the cur­tain in No­vem­ber 2021 with $125 mil­lion in fi­nanc­ing. The biotech big­wigs don’t stop there at Chro­ma, as for­mer No­var­tis and Cel­gene busi­ness de­vel­op­ment ex­ec George Golumbes­ki takes his seat on the board of di­rec­tors. Golumbes­ki, a part­ner at DROIA Ven­tures, chairs the boards of Shat­tuck Labs and Car­rick Ther­a­peu­tics and is on the board at Sage and Mor­phoSys.

Noubar Afeyan

Noubar Afeyan has been named chair­man of the board at one of his Flag­ship com­pa­nies, Ru­bius Ther­a­peu­tics, whose stock has plum­met­ed fur­ther even when the red blood cell biotech tried to play up da­ta at AACR in April. Afeyan un­veiled an­oth­er com­pa­ny on Thurs­day as pro­tein up­start Pro­Found Ther­a­peu­tics made its de­but with $75 mil­lion at their dis­pos­al.

Xavier Avat has joined Lin­da Mar­bán’s crew at Duchenne biotech Capri­cor Ther­a­peu­tics as CBO. Avat took charge of Latin Amer­i­ca op­er­a­tions and then led the So­val­di launch in al­most sev­en years at Gilead. Since leav­ing San­ten Phar­ma­ceu­ti­cal in 2017, he had been SVP, glob­al cor­po­rate strat­e­gy and new ini­tia­tives at Irvine, CA medtech Ed­wards Life­sciences.

Ed­dine Sa­iah

Ver­santbacked Sta­blixTony Kings­ley’s post-Schol­ar Rock land­ing spothas ush­ered in Ed­dine Sa­iah as CSO and pro­mot­ed co-founder Kevin Sprott to COO. Sa­iah had held the same post to close out sev­en years at Nav­i­tor Phar­ma­ceu­ti­cals, while Sprott had been Sta­blix’s SVP of drug dis­cov­ery be­fore shift­ing to the C-suite. Among oth­er in­vestors, New En­ter­prise As­so­ci­ates and Cor­morant As­set Man­age­ment chipped in on the New York biotech’s $63 mil­lion Se­ries A in June 2021.

Neil War­ma

→ Seoul-based Genex­ine is reel­ing in Neil War­ma as pres­i­dent and CEO. War­ma joins Genex­ine af­ter a stint as gen­er­al man­ag­er of I-Mab Bio­phar­ma US. Pri­or to that, War­ma held a near­ly decade-long ca­reer as pres­i­dent, CEO and di­rec­tor of Opexa Ther­a­peu­tics. Ear­li­er in his ca­reer, War­ma served as pres­i­dent, CEO and di­rec­tor of Vi­ron Ther­a­peu­tics, co-found­ed MedEx­act, and served in roles at No­var­tis.

Dray­ton Wise

→ With its non-cys­tic fi­bro­sis bronchiec­ta­sis drug brenso­cat­ib ad­vanc­ing to Phase III, In­smed has el­e­vat­ed Dray­ton Wise to chief com­mer­cial of­fi­cer, lead­ing the way on com­mer­cial­iza­tion strate­gies for its re­frac­to­ry MAC lung dis­ease treat­ment Arikayce. Wise joined In­smed in 2014 af­ter 15 years at No­var­tis, and he had served as head of US and gen­er­al man­ag­er of Arikayce since No­vem­ber 2019. To con­clude his tenure at the phar­ma gi­ant, he was na­tion­al di­rec­tor, cys­tic fi­bro­sis sales & ac­count man­age­ment.

→ Car­dio and meta­bol­ic dis­ease play­er An­thos Ther­a­peu­tics has added Drew Young in­to the fold as chief com­mer­cial of­fi­cer and head of pa­tient ex­pe­ri­ence. Young had two sep­a­rate stints with Bris­tol My­ers (1991-2001 and 2005-11), and in the lat­ter, he took on such roles as busi­ness di­rec­tor, CV/meta­bol­ics for the north­east US re­gion. He then moved on to Bio­gen and EMD Serono be­fore a brief stay as Hori­zon’s group VP and gen­er­al man­ag­er, gout busi­ness unit.

Sue Ash­well

→ Led by ex-Black Di­a­mond CSO Christo­pher Roberts and con­cen­trat­ing on be­ta-pro­peller pro­teins to treat can­cer, Civet­ta Ther­a­peu­tics has made a pair of moves with Jesse Smith as CSO and Sue Ash­well as SVP of chem­istry. Smith spent eight years at Epizyme be­fore jump­ing to Omega Ther­a­peu­tics in 2018 as SVP of ear­ly dis­cov­ery, and most re­cent­ly he was SVP of bi­ol­o­gy at Remix Ther­a­peu­tics. Af­ter 10 years with As­traZeneca, Ash­well was se­nior di­rec­tor in med­i­c­i­nal chem­istry with For­ma Ther­a­peu­tics. Be­fore this new post at Civet­ta, Ash­well had been head of med­i­c­i­nal chem­istry at UCB by way of Ra Phar­ma­ceu­ti­cals.

Peng Leong

→ Backed by An­dreessen Horowitz and beef­ing up its pipeline by dust­ing off an old Am­gen drug last year, BioAge Labs has giv­en busi­ness chief Peng Leong ad­di­tion­al re­spon­si­bil­i­ties as head of brain ag­ing. Be­fore jump­ing on board at BioAge in 2019, Leong al­so held the CBO post at Kazia Ther­a­peu­tics, and among ear­li­er roles, he was head of gen­er­al med­i­cine busi­ness de­vel­op­ment dur­ing his time at Mer­ck KGaA. BioAge will get some stout com­pe­ti­tion in the an­ti-ag­ing space from Rick Klaus­ner’s Al­tos Labs, which will be helmed by ex-GSK R&D chief Hal Bar­ron.

Lo­ri­anne Ma­suo­ka

→ Fo­cused on Dravet syn­drome and oth­er types of epilep­sy, Epy­genix Ther­a­peu­tics out of Para­mus, NJ has se­lect­ed Lo­ri­anne Ma­suo­ka as CMO. From 2017-19, Ma­suo­ka — the ex-med­ical chief of Nek­tar and Cu­bist Phar­ma­ceu­ti­cals — was CMO of Mar­i­nus Phar­ma­ceu­ti­cals, which gar­nered its first FDA ap­proval with Ztalmy (ganax­olone) for seizures as­so­ci­at­ed with CD­KL5 de­fi­cien­cy dis­or­der (CDD) in March. Ma­suo­ka is al­so a board mem­ber at Opi­ant Phar­ma­ceu­ti­cals.

→ Look­ing to sep­a­rate them­selves from oth­er DNA se­quenc­ing peers with a $276 mil­lion Se­ries C round last sum­mer, San Diego-based El­e­ment Bio­sciences has in­stalled Mark Aitken­head as chief com­mer­cial of­fi­cer. Af­ter Ther­mo Fish­er ac­quired In­vit­ro­gen in 2014, Aitken­head was the CRO ti­tan’s glob­al com­mer­cial leader for the clin­i­cal next gen­er­a­tion se­quenc­ing (NGS) di­vi­sion and, to round out his tenure, the gen­er­al man­ag­er for cel­lu­lar analy­sis in­stru­men­ta­tion.

Lau­ra Tres­pi­di

Beck­ley Psytech, the “toad ven­om” psy­che­delics play­er out of Ox­ford that scored an $80 mil­lion Se­ries B last Au­gust, has ap­point­ed Lau­ra Tres­pi­di as chief de­vel­op­ment of­fi­cer. Part of Bob Dug­gan’s team at Sum­mit Ther­a­peu­tics as SVP, CMC, sup­ply chain and tech­ni­cal op­er­a­tions, Tres­pi­di al­so brings CMC ex­pe­ri­ence from Shire, where she worked from 2007-14.

Ar­i­an Pano has signed on to be CMO of Salu­bris Bio­ther­a­peu­tics, a Gaithers­burg, MD biotech whose lead as­set JK07 is in Phase I tri­als for heart fail­ure with re­duced ejec­tion frac­tion (HFrEF). Pano comes to Salu­bris from Kiniksa, where he was chief clin­i­cal de­vel­op­ment of­fi­cer, and ear­li­er he took on the roles of SVP, clin­i­cal de­vel­op­ment, US coun­try head and glob­al head of safe­ty si­mul­ta­ne­ous­ly at Gala­pa­gos.

Brady John­son

→ Mul­ti­spe­cif­ic drug de­vel­op­er Ten­tar­ix Bio­ther­a­peu­tics, which launched in Oc­to­ber 2021 with a $50 mil­lion Se­ries A, has filled a num­ber of po­si­tions, start­ing with Brady John­son, who climbs aboard as SVP, fi­nance and op­er­a­tions af­ter sev­en years as VP, fi­nance and prin­ci­pal ac­count­ing of­fi­cer at Cidara Ther­a­peu­tics. Oys­ter Point Phar­ma chair­man and ex-Hy­pe­r­i­on CEO Don­ald San­tel has been named chair­man at Ten­tar­ix, while Tom Bu­mol — the ex­ec­u­tive di­rec­tor of the Allen In­sti­tute for Im­munol­o­gy who re­tired from Eli Lil­ly af­ter 35 years in 2017 — has al­so been elect­ed to the board. Fi­nal­ly, Ten­tar­ix has set up a sci­en­tif­ic ad­vi­so­ry board con­sist­ing of Bu­mol, Bri­an Kuhlman and John Tei­jaro.

Michelle Gilson

→ Tun­ing out the mar­ket may­hem with a $123 mil­lion IPO in Feb­ru­ary, Gaithers­burg, MD-based CAR-T de­vel­op­er Ar­cel­lx has lined up Michelle Gilson as CFO. A Jef­feries and Gold­man Sachs alum, Gilson makes the leap to biotech af­ter four years as se­nior eq­ui­ty re­search an­a­lyst and man­ag­ing di­rec­tor for Canac­cord Ge­nu­ity.

→ Gilead an­tivi­ral vet Ken­neth Cundy has been named CSO of Aneb­u­lo Phar­ma­ceu­ti­cals, which start­ed list­ing on Nas­daq in May 2021 and is fo­cused on cannabi­noid over­dose and sub­stance abuse dis­or­der. Cundy left Gilead in 2000 and then had a 14-year run at Xeno­Port, where he rose to CSO. Since 2014, he had been chief sci­en­tist at mi­tochron­dria-dri­ven Co­hBar.

Paul Brooks

→ Or­gan-on-a-chip com­pa­ny CN Bio has tapped Paul Brooks as CBO. Brooks joins the Cam­bridge, UK-based com­pa­ny from Hori­zon Dis­cov­ery, serv­ing as head of busi­ness op­er­a­tions & man­ag­ing di­rec­tor. Pri­or to that, Brooks was with Sig­ma-Aldrich — which was lat­er ac­quired by Mer­ck Group to form Mil­li­pore­Sig­ma, where he served as head of dis­cov­ery re­search ser­vices & gen­er­al man­ag­er. Be­fore that, Brooks was CCO, ex­ec­u­tive di­rec­tor and board mem­ber of Ox­ford Ge­net­ics.

→ There’s Big Phar­ma and then there’s Small Phar­ma. The Lon­don-based com­pa­ny — fo­cused on the de­vel­op­ment of short-act­ing psy­che­del­ic-as­sist­ed ther­a­pies for men­tal health con­di­tions — has brought in Alas­tair Rid­dell as COO. Rid­dell takes over from Marie Layzell, who will be tran­si­tion­ing to the role of chief man­u­fac­tur­ing and de­vel­op­ment of­fi­cer. Rid­dell makes his way to Small Phar­ma with ex­pe­ri­ence from Phar­ma­gene (CEO), Par­a­digm Ther­a­peu­tics (CEO), Stem Cell Sci­ences (CEO) and Feed­back (chair­man).

Chau Khuong

→ On the heels of rak­ing in $381 mil­lion at the start of this month with Catalio Nexus Fund III, Catalio Cap­i­tal Man­age­ment has picked up Chau Khuong as gen­er­al part­ner. Khuong said good­bye to Or­biMed af­ter near­ly 20 years as a pri­vate eq­ui­ty part­ner at the VC, and he’s been a board mem­ber at a pletho­ra of biotechs, in­clud­ing cur­rent board seats at Galec­to and Fu­sion Phar­ma­ceu­ti­cals.

→ San Fran­cis­co-based Shasqi has ush­ered in Steve Abel­la as CMO and Scott Wieland as SVP of clin­i­cal de­vel­op­ment. Abel­la hops aboard Shasqi af­ter serv­ing as CMO at Vi­da De­vel­op­ment Sci­ences and Bio­Clin Ther­a­peu­tics. Pri­or to that, Abel­la was se­nior di­rec­tor at Gilead and ex­ec­u­tive di­rec­tor at Am­gen.

Mean­while, Wieland most re­cent­ly served as EVP of de­vel­op­ment at nanomed­i­cine com­pa­ny Nanobi­otix and jump­start­ed his ca­reer lead­ing the be­hav­ioral phar­ma­col­o­gy lab at Co­Cen­sys.

Shan­non Mor­ris

→ San Diego can­cer play­er Eras­ca has bol­stered its clin­i­cal team with Shan­non Mor­ris (SVP of clin­i­cal de­vel­op­ment) and Amy Grekow­icz Park­er (VP of clin­i­cal op­er­a­tions). Mor­ris, a GSK alum who was VP of clin­i­cal de­vel­op­ment at G1 Ther­a­peu­tics, held that same ti­tle at Is­tari On­col­o­gy un­til this lat­est move to Eras­ca. Dur­ing Park­er’s time at Pfiz­er, she was in­volved in the NDAs for Su­tent and PARP in­hibitor Talzen­na, and she re­cent­ly served as VP of clin­i­cal op­er­a­tions for Onc­ter­nal Ther­a­peu­tics. Eras­ca has al­so tapped Big Phar­ma vet John Lo as se­nior com­mer­cial ad­vi­sor and mem­ber of the re­search, de­vel­op­ment, and com­mer­cial ad­vi­so­ry board.

Mon­i­ca An­der­sen

→ Ra­dio­phar­ma­ceu­ti­cals-fo­cused North­Star Med­ical Ra­dioiso­topes has signed on Mon­i­ca An­der­sen as VP, hu­man re­sources. Most re­cent­ly, An­der­sen served in the same role over at Mallinck­rodt Phar­ma­ceu­ti­cals and Co­vi­di­en. Pri­or to those stints, An­der­sen was VP, hu­man re­sources at First Da­ta Re­sources, West­ern Union and Gen­er­al Elec­tric Com­pa­ny, among oth­ers.

Chi­to Zu­lue­ta

→ We have some board changes to sift through at Amarin, where re­cent­ly re­tired Eli Lil­ly ex­ec Chi­to Zu­lue­ta and Pret­ty­brook man­ag­ing part­ner Erin En­right have clinched spots and Mer­ck car­dio­vas­cu­lar vet Per Wold-Olsen has been named chair­man. David Stack and Joe Za­krzews­ki, who were board mem­bers for the past decade, are re­tir­ing af­ter Amarin’s an­nu­al meet­ing in June.

William Hei­den has suc­ceed­ed Paulo Cos­ta as chair­man of the board at Macro­Gen­ics. Hei­den, the pres­i­dent and CEO of AM­AG Phar­ma­ceu­ti­cals from 2012-20, al­so holds a board seat at Atara Bio­ther­a­peu­tics and is chair­man of Third Pole Ther­a­peu­tics.

Robin Wash­ing­ton

Roger Perl­mut­ter has ex­pand­ed the board of di­rec­tors at Eikon Ther­a­peu­tics by bring­ing in Robin Wash­ing­ton. The Al­pha­bet board mem­ber who re­tired as CFO of Gilead in 2019, Wash­ing­ton will hold a board seat at Eikon along­side Perl­mut­ter, ex-Mer­ck chief Ken Fra­zier and Fore­site’s Jim Tanan­baum, among oth­ers.

Con­tra­Fect pres­i­dent, CEO and chair­man Roger Pomer­antz has been named vice chair­man of Is­raeli im­munother­a­py biotech En­livex. Pomer­antz, the one-time glob­al head of in­fec­tious dis­eases for J&J and a for­mer Mer­ck ex­ec, al­so led Seres Ther­a­peu­tics from 2014-19.

Philip Low

→ Amid a huge shake­up at the top, the ac­qui­si­tion of Novos­teo and a pend­ing name change to Quince Ther­a­peu­tics, Cor­texyme has opened up space for Philip Low on the board of di­rec­tors. Low’s ap­point­ment comes af­ter its un­con­ven­tion­al ap­proach to Alzheimer’s flopped, lead­ing to lay­offs and the de­par­tures of se­nior lead­er­ship, in­clud­ing found­ing CEO Casey Lynch. Low, a Pur­due pro­fes­sor since 1976, has ei­ther found­ed or co-found­ed such biotechs as Umo­ja Bio­phar­ma, En­do­cyte, and yes, Novos­teo.

→ Buck­ing the bear mar­ket trend with a $140 mil­lion SPAC deal to cat­a­pult its sub­sidiary Scilex to Nas­daq, Sor­ren­to Ther­a­peu­tics has added Tam­my Reil­ly to the board of di­rec­tors. Now the man­ag­ing part­ner of the ad­vi­so­ry firm she found­ed, TRDx, Reil­ly closed out her 15 years at Roche in 2005 as EVP for on­col­o­gy and der­ma­tol­ogy.

Jill DeS­i­mone

Prax­is Pre­ci­sion Med­i­cines has elect­ed Jill DeS­i­mone to the board of di­rec­tors as its clin­i­cal hold con­tin­ues with its epilep­sy drug PRAX-222. DeS­i­mone just left Mer­ck af­ter eight years as pres­i­dent of US on­col­o­gy and spent 32 years at Bris­tol My­ers.

→ For­mer Heron Phar­ma­ceu­ti­cals CFO Robert Hoff­man is tak­ing over the reins as the An­tibe Ther­a­peu­tics’ new chair of its board of di­rec­tors. Hoff­man has served on An­tibe’s board since late 2020. Pri­or to his stint at Heron, Hoff­man had a long ca­reer at Are­na Phar­ma­ceu­ti­cals, cul­mi­nat­ing in his ti­tle of CFO. Cur­rent­ly, Hoff­man is pres­i­dent, CEO and chair­man of Kin­tara Ther­a­peu­tics and sits on the boards of ASLAN Phar­ma­ceu­ti­cals and Fi­bro­Bi­o­log­ics.

In ad­di­tion, the com­pa­ny an­nounced the ap­point­ments of Walt Mac­nee, out­go­ing chair, and CSO, di­rec­tor and founder John Wal­lace as vice chairs.

Naveed Shams

→ Dal­las-based Nanoscope Ther­a­peu­tics is bring­ing in Naveed Shams and Thomas Ciul­la as ad­vi­sors to the com­pa­ny’s board and man­age­ment. Shams most re­cent­ly served as CSO of Pro­QR Ther­a­peu­tics and was the for­mer pres­i­dent and CEO of San­ten. Shams, in his ca­reer, has al­so had stints at No­var­tis and Genen­tech/Roche. Ciul­la cur­rent­ly serves as CMO and chief de­vel­op­ment of­fi­cer of Clear­side Bio­med­ical and for­mer­ly had gigs at Spark Ther­a­peu­tics and Oph­thotech.

→ Irish biotech Rem­e­dy­Bio is wel­com­ing So­phie Pa­pa (CMO at Enara Bio); Si­mon Chowd­hury (vis­it­ing fel­low at Har­vard Med­ical School and the Dana-Far­ber In­sti­tute); and Luke O’Neill (chair of bio­chem­istry at Trin­i­ty Col­lege Dublin) to the team with the cre­ation of the com­pa­ny’s sci­en­tif­ic ad­vi­so­ry board.

2023 Spot­light on the Fu­ture of Drug De­vel­op­ment for Small and Mid-Sized Biotechs

In the context of today’s global economic environment, there is an increasing need to work smarter, faster and leaner across all facets of the life sciences industry.  This is particularly true for small and mid-sized biotech companies, many of which are facing declining valuations and competing for increasingly limited funding to propel their science forward.  It is important to recognize that within this framework, many of these smaller companies already find themselves resource-challenged to design and manage clinical studies themselves because they don’t have large teams or in-house experts in navigating the various aspects of the drug development journey. This can be particularly challenging for the most complex and difficult to treat diseases where no previous pathway exists and patients are urgently awaiting breakthroughs.

Up­dat­ed: FDA re­mains silent on or­phan drug ex­clu­siv­i­ty af­ter last year's court loss

Since losing a controversial court case over orphan drug exclusivity last year, the FDA’s Office of Orphan Products Development has remained entirely silent on orphan exclusivity for any product approved since last November, leaving many sponsors in limbo on what to expect.

That silence means that for more than 70 orphan-designated indications for more than 60 products, OOPD has issued no public determination on the seven-year orphan exclusivity in the Orange Book, and no new listings of orphan exclusivity appear in OOPD’s searchable database, as highlighted recently by George O’Brien, a partner in Mayer Brown’s Washington, DC office.

Val­neva's chikun­gun­ya vac­cine on track for FDA nod af­ter long-term an­ti­body da­ta

The chikungunya virus met its match in Valneva’s vaccine candidate, VLA1553, according to data from an antibody persistence trial released today.

The trial found that 99% of 363 participants retained neutralizing antibodies 12 months after a single dose of vaccine in the company’s earlier, larger Phase III trial, called VLA1553-301. The participants from the long-term study will continue to be monitored for at least five years.

Big week for Alzheimer’s da­ta; As­traZeneca buys cell ther­a­py start­up; Dig­i­tal ther­a­peu­tics hits a pay­er wall; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

You may start to notice more stories exclusively available to Premium subscribers. This week alone, paid subscribers can read our in-depth reporting on Alzheimer’s data, digital therapeutics and Allogene’s cell therapy for solid tumors, as well as scoops on Twitter ads and Catalent. With your support, we can keep growing our team and spend more time on quality work. We have both individual and company plans available — check them out to unlock the full Endpoints experience.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.

Am­gen, years be­hind ri­vals, says PhI obe­si­ty drug shows dura­bil­i­ty signs

While NBC ran “The Biggest Loser” for 17 seasons, deemed toxic by critics for the reality show’s punishing exercise and diet upheavals, researchers in pharmaceutical labs have been attempting to create prescription drugs that induce weight loss — and one pharma betting it can require less frequent dosing is out with a new crop of data.

Amgen was relatively late to the game compared to its approved competitor Novo Nordisk and green light-approaching rival Eli Lilly. But early data suggested Amgen’s AMG 133 led to a 14.5% weight reduction in the first few months of dosing, buoying shares earlier this fall, and now the California pharma is out with its first batch of durability data showing that figure fell slightly to 11.2% about 150 days after the last dose. Amgen presented at the 20th World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease on Saturday afternoon.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.

Illustration: Assistant Editor Kathy Wong for Endpoints News

As mon­ey pours in­to dig­i­tal ther­a­peu­tics, in­sur­ance cov­er­age crawls

Talk therapy didn’t help Lily with attention deficit hyperactivity disorder, or ADHD. But a video game did.

As the 10-year-old zooms through icy waters and targets flying creatures on the snow-capped planet Frigidus, she builds attention skills, thanks to Akili Interactive Labs’ video game EndeavorRx. She’s now less anxious and scattered, allowing her to stay on a low dose of ADHD medication, according to her mom Violet Vu.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Eli Lil­ly’s Alzheimer’s drug clears more amy­loid ear­ly than Aduhelm in first-ever head-to-head. Will it mat­ter?

Ahead of the FDA’s decision on Eli Lilly’s Alzheimer’s drug donanemab in February, the Big Pharma is dropping a first cut of data from one of the more interesting trials — but less important in a regulatory sense — at an Alzheimer’s conference in San Francisco.

In the unblinded 148-person study, Eli Lilly pitted its drug against Aduhelm, Biogen’s drug that won FDA approval but lost Medicare coverage outside of clinical trials. Notably, the study didn’t look at clinical outcomes, but rather the clearance of amyloid, a protein whose buildup is associated with Alzheimer’s disease, in the brain.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.

US month­ly costs for biosim­i­lars 'sub­stan­tial­ly high­er' than Ger­many or Switzer­land, JA­MA re­search finds

As the global biologics market is expected to hit nearly the half-trillion-dollar mark this year, new JAMA research points to the importance of timely biosimilar entry, particularly as fewer biosimilars are entering the US than in Europe, and as monthly treatment costs for biosimilars were “substantially higher” in the US compared with Germany and Switzerland.

Among the three countries, biosimilar market share at launch was highest in Germany, but increased at the fastest rate in the US, the authors from the University of Zurich’s Institute of Law wrote in JAMA Network Open today.

Kirk Myers is shown in a still image from a new film series showcasing the efforts of HIV advocates funded by Gilead.

Gilead spot­lights HIV projects and the com­mu­ni­ty lead­ers dri­ving them in new mi­ni-doc­u­men­tary films

Gilead is going behind the scenes of some of the HIV initiatives it funds through grants in a new film series narrated by the people helming the projects.

The first four films and leaders come from across the US — Arianna Lint in Florida and Puerto Rico, Cleve Jones in San Francisco, June Gipson in Mississippi and Kirk Myers in Texas. Their HIV-focused efforts range from addressing unmet needs of the transgender community to delivering social services and high-quality health care in underserved communities.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.